Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.
Aclaris Therapeutics (NASDAQ: ACRS) has initiated a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept trial of its bispecific anti-TSLP/IL-4Rα antibody ATI-052 in asthma, following a Phase 1b start in atopic dermatitis.
The ~16-patient study (3:1 randomization) will assess safety, tolerability, PK, PD biomarkers including FeNO and blood eosinophils, and FEV1. Top-line results for both POC trials are expected in the second half of 2026, with a Phase 2b program planned for H2 2026.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in two healthcare conferences in February 2026 with senior management presentations and webcasts available.
On Feb 12, 2026 at 2:30 PM EST CEO Dr. Neal Walker will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit. On Feb 26, 2026 at 8:40 AM EST President COO Hugh Davis will present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. Webcasts will be available on the company website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported preclinical results showing its oral ITK/JAK3 inhibitor ATI-2138 produced rapid, near-complete, and sustained hair regrowth in a validated murine reversal model of alopecia universalis versus control and ritlecitinib.
At 300 ppm in chow, mean hair regrowth was 37% at week 2, 87% at week 4, and 93% at week 6 for ATI-2138 versus 25%, 48%, and 78% respectively for ritlecitinib. ATI-2138 is highly selective for ITK and JAK3 (>1,000-fold versus other JAKs). Aclaris expects to initiate a Phase 2b trial in H1 2026.
Aclaris Therapeutics (NASDAQ: ACRS) has initiated a randomized (3:1), blinded, placebo-controlled Phase 1b proof-of-concept trial in atopic dermatitis (AD) for ATI-052, a bispecific anti-TSLP/IL-4Rα antibody. The company cited positive Phase 1a interim results showing a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics at low dose. The Phase 1b AD trial will assess safety, EASI, IGA response, PP-NRS, PK, and PD using lesional and non-lesional skin tape strips. Aclaris expects to start a second Phase 1b POC trial in asthma in Q1 2026 and to report topline results from both POC trials in H2 2026.
Aclaris Therapeutics (NASDAQ: ACRS) reported positive interim Phase 1a SAD/MAD results for its anti-TSLP/IL-4Rα bispecific antibody ATI-052 on January 6, 2026. The randomized, blinded, placebo-controlled study in healthy adults tested single doses (30, 120, 360, 720 mg) and multiple doses (240, 480 mg).
Key findings: favorable safety with no Grade 3 drug-related TEAEs or serious adverse events, predominant Grade 1 TEAEs, PK half-life ≥26 days, dose-proportional Cmax/AUC, and robust PD target inhibition including near-complete TSLP/IL-4 pathway suppression lasting ≥6 weeks at 360 mg. Company expects Phase 1b POC trials in AD and asthma in Q1 2026 and plans a Phase 2b AD trial in H2 2026.
Aclaris Therapeutics (NASDAQ: ACRS) was added to the Nasdaq Biotechnology Index (NBI), effective at the close of trading on December 19, 2025. The NBI tracks securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and uses a modified capitalization-weighted methodology.
The company met NBI eligibility requirements, including minimum market capitalization, average daily trading volume and public company seasoning; the index is evaluated annually each December.
Aclaris Therapeutics (NASDAQ: ACRS) said CEO Dr. Neal Walker and senior leadership will join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City.
The discussion is scheduled for Tuesday, December 2, 2025 at 11:00 AM EST. A live and archived webcast will be available on the company Events page at aclaristx.com and will remain accessible for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 2025 results and a corporate update highlighting clinical progress and financial position. The company posted positive Phase 2a topline and EADV presentation data for ITK/JAK3 inhibitor ATI-2138 (week 4 EASI -77%, BSA -64%, PP-NRS -45%) and plans a Phase 2 in an additional indication in H1 2026. Topline readouts for bispecific ATI-052 Phase 1a and anti-TSLP bosakitug Phase 2 are expected in early and H2 2026, respectively. Cash, cash equivalents and marketable securities were $167.2M as of Sept 30, 2025, with a runway into H2 2028. Q3 net loss widened to $14.6M.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in three healthcare conferences in November 2025 with senior leadership presenting fireside chats.
Key events: Guggenheim on Nov 12, 2025 at 11:00 AM EST (Dr. Neal Walker et al.); Stifel on Nov 12, 2025 at 1:20 PM EST (Dr. Hugh Davis et al.); and Jefferies Global on Nov 17, 2025 at 2:00 PM GMT / 9:00 AM EST (Dr. Walker).
Live and archived webcasts will be available on the company Events page and accessible on the Aclaris website for at least 30 days.
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company, will host its 2025 R&D Day on October 14, 2025 in New York. The event will focus on the company's development of kinase and immune pathway inhibitor franchises for immuno-inflammatory diseases.
The presentation will feature insights from company leadership and expert speakers, including Dr. Zuzana Diamant and Dr. Michael C. Cameron. Key topics include the company's progress in developing small and large molecule candidates, their innovative discovery platform, ITK inhibition franchise, TSLP franchise development, and updates on ongoing clinical trials.